Previous studies of biomarkers in tumor tissues have shown that the mutation status of genes known to be associated with CRC carcinogenesis (NRAS, KRAS, and BRAF) and defects in the DNA mismatch repair system, exert substantial effects on the treatment decision.27 This evidence concerns the gene BRAF and neoplasm.